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Abstract 
 
Leishmania donovani, a protozoan parasite, is the causative agent of the often fatal 
disease visceral leishmaniasis.  The current treatments available are minimal and toxic to the 
patient.  It has been shown that these organisms exhibit lipolytic activity during their growth in 
vitro.  Lipases are enzymes that are known to aid in the development and virulence of several 
pathogenic organisms such as Candida albicans and Staphylococcus warneri.  Little information 
is known, however, about the role of lipases in Leishmania species. We hypothesize that lipase 
may play a part in Leishmania’s ability to survive within the human host as well as its 
pathogenesis.  In past studies, the L. donovani secretory lipase gene (LdLip3) was episomally 
expressed with an HA tag by transfected promastigotes. The purified protein was tested for 
enzyme activity by performing assays with McIlvaine’s buffer pH 4-8 at 26°C, 37°C, and 42°C 
using 4MU-palmitate as a substrate.  The results showed that there was an average thirtyfold 
increase in specific activity when comparing the purified protein to the unpurified supernatant 
samples. Furthermore, metal ions are known to be cofactors of a variety of enzymes, greatly 
affecting their activity, hence, in the current study a panel of metal ions was tested to determine 
their effect on the activity of purified LdLip3. Optimal conditions for this enzyme were 
established at pH 8, 42°C, with the addition of Zn+2, whereas the addition of Mn+2 consistently 
produced a strong inhibitory effect.  We are currently in the process of validating this previously 
collected data via the same experimentation protocol to determine reproducibility.  Chelating 
agent studies with EDTA, also underway, will determine if the effect of metal ions on the 
enzyme activity could be reversed. Thus far, EDTA has countered the addition of the cofactors.  
Future studies include inhibitory studies with organophosphates that have been shown to inhibit 
lipases, in the hope to develop new drug targets for this parasite. 
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Introduction 
Leishmania donovani is a unicellular parasite that takes up residence in its host’s 
macrophages causing visceral damage.  Like all other eukaryotes, Leishmania shares the same 
basic morphological features.  The pathogen has a nucleus, which stores DNA, and 
compartmentalized organelles.  Its genome is rich in guanine-cytosine base pairs and contains no 
introns, an uncommon aspect in the Eukaryota domain.  Also within the cell, unique to the class 
Kinetoplastida, is a kinetoplast, a network of mini- and maxicircular DNAs inside a large 
mitochondrion which encode the substrates for RNA editing.  This is the organism’s only 
mitochondrion (Roy et al 2008).  This kDNA system most likely evolved from a highly 
supercoiled plasmid “harbored within the mitochondrion of an ancient flagellate” (Lukes et al 
2002).  Additionally, leishmanial species possess a lipophosphoglycan coat that sheaths the 
entire cell’s outside surface, which is involved in modulating the host’s immune response, 
promoting the parasite’s survival (Turco and Descoteaux 1992).  This layer atop the surface 
membrane is a mechanism used by a number of other parasites such as Trypanosoma brucei and 
Plasmodium falciparum.   
Leishmania donovani primarily causes visceral leishmaniasis, also known as kala-azar, 
black fever, or dumdum fever, which is classified as the most severe form of leishmaniasis.  For 
those people who do not harbor a silent infection, the patient clinically presents with symptoms 
including, but not limited to, fever, hepatosplenomegaly, fatigue, and leukopenia.  Fatal if left 
untreated, the infection is evident from a distended abdomen, caused by the enlargement of the 
liver and spleen.  This swelling is due to an acute infection of these major organs as well as the 
bone marrow, ultimately destroying the patient’s immune system.  The disease has a mortality 
rate as high as 100% within just two years (“Leishmaniasis”).  Other forms of leishmaniasis 
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consist of wet cutaneous lesions, sometimes resembling leprosy, on the skin or within the host’s 
mucous membranes.  In these forms, only the macrophages within the reticuloendothelial system 
are infected.  Not typically fatal, yet still horrific to the patient, the cutaneous forms heal within a 
few months leaving scars. 
According to Dr. Robert Killick-Kendrick with the World Health Organization (WHO), 
as of 2010, there are on average 500,000 new cases of visceral leishmaniasis worldwide each 
year and of these, ten-percent of them result in death.  These numbers are not known with 
certainty however.  He continues by explaining that “leishmaniasis is not a notified disease in 
many countries and therefore these figures are underestimates,” (Kendrick 2010).  The 
devastating disease has a parasitic fatality rate that comes in second only to malaria (Chappuis et 
al 2007) and the future holds no reassurance.  Both incidence and mortality rates have steadily 
increased in the past five years and the parasite threatens new areas as it spreads across Middle 
Eastern and South American regions, exposing more people to its severity (Bhattarai et al 2010).  
This dispersion could possibly be due to climate change and its effect on the sandfly vector 
(González et al 2010).  A more recent study conducted by the WHO Leishmaniasis Control 
Team suggests that this neglected tropical disease remains just as prevalent today, if not more so, 
and remains a deep concern for people in endemic countries (Alvar et al 2012).   
Visceral leishmaniasis is found in both Old World (eastern hemisphere) and New World 
(western hemisphere) countries, where climates are mild to temperate.  Tropical and subtropical 
regions, as well as in southern Europe along the Mediterranean are hotspots for the disease.  Its 
epidemiology is far reaching, existing in a total of ninety eight countries across almost every 
continent, being endemic in highly populated, yet underdeveloped nations such as Sudan, India, 
Iraq, Brazil, and Bangladesh (“Parasites-Leishmaniasis”).  Current numbers put more than 
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twenty five-percent of the entire world’s population at risk for contracting visceral leishmaniasis 
(Alvar et al 2012).  Furthermore, United States soldiers are being deployed to places considered 
high threat areas to fight during military Operations Iraqi and Enduring Freedom.  Over a two 
year span, four U.S. soldiers returned from tours in Iraq and Afghanistan, infected with visceral 
leishmaniasis, while over 200,000 soldiers came back infected with cutaneous leishmaniasis 
(Myles et al 2007; Pehoushek et al 2004).   
Leishmania donovani is transmitted to humans and other mammalian reservoir hosts, 
such as canines and rodents, via an insect vector.  The bite of an infected gravid female sandfly 
will deposit the parasite into the definitive host’s bloodstream.  Phlebotomus sandfly species 
typically transport the parasite in the Old World and Lutzomyia sandflies are the carriers in the 
New World (Lewis 1971).  Leishmania species have two main phases in their life cycle, each 
characterized by distinct morphological and perhaps physiological differences.  To begin, the 
organism starts as a flagellated, extracellular promastigote found within the midgut of its 
intermediate host, the sandfly.  Promastigotes are teardrop shaped and their flagellum is located 
at the anterior end of the cell body.  When the sandfly takes a blood meal, the metacyclic, or 
infectious, parasites thriving in the foregut pass through the insect’s proboscis and are injected 
into the new host’s circulatory system.  Host macrophages then phagocytize the foreign free 
swimming promastigotes.  The ingested parasites transform into the amastigote stage within the 
phagolysosome.  Amastigotes are circular, non-flagellated obligate intracellular cell bodies and 
are among the smallest known eukaryotic cells.  They continuously multiply via mitosis until the 
actual macrophage bursts, releasing thousands of parasites back into the bloodstream where they 
subsequently find refuge in various other tissues.  The cycle repeats itself when another sandfly 
feeds on the infected host, taking up the amastigotes, where they again transform into the 
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promastigote stage.  Amastigotes are the causative agents of disease.  Throughout the entire 
Leishmania genus the same dichotomic life cycle is observed (Shakarian et al 2010). 
Treating visceral leishmaniasis poses a twofold problem.  Leishmania cells hide and 
thrive within the host’s immune system, specifically the phagolysosome, in conditions that were 
meant to destroy them.  This makes targeting the actual parasite, rather the symptoms, difficult.  
Secondly, due to the parasite’s intracellular nature for the majority of its life cycle, killing it 
results in the destruction of the host’s cells as well, both normal and infected, making drugs that 
successfully combat the disease extremely toxic.  
Diagnosis of visceral leishmaniasis should be absolutely certain before treatment begins 
to ensure no unnecessary damage to the patient.  Also, every case should be taken on an 
individualized basis where factors such as species and location of contraction are noted.  The 
first line of treatment for the disease is pentavalent antimonial (SbV) compounds.  These drugs 
have been the staple for leishmaniasis treatment since the 1940s, but are not licensed for 
commercial use in the U.S., rather are strictly available through the Centers for Disease Control 
and Prevention (CDC).  Sodium stibogluconate (Pentostam®) can be delivered intravenously or 
intramuscularly at a high volume per dose, 20 mg Sb/kg/day for about twenty days.  The drug 
works by reducing fructose diphosphate and inhibiting glycolysis (Frezard et al 2009).  Sodium 
antimony gluconate (SAG) is another common drug used to treat visceral leishmaniasis.  For 
twenty-eight days 20 mg/kg is pumped throughout the body (Abdo et al 2003).  The mechanism 
of action for SAG involves the induction of reactive oxygen species and nitric oxide via 
phosphoinositide 3-kinase and mitogen-activated protein kinase activation.  This is imperative 
information recently discovered by Basu et al (2006) which “has provided the first evidence that 
SAG treatment induces activation of some important components of the intracellular signaling 
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pathway.”  Another drug used is meglumine antimoniate (Glucantime®).  Some of the side 
effects for antimony containing drugs include arthralgia, myalgia, pancreatitis, acute renal 
failure, and cardiotoxicity.  Relatively effective, these antimonial compounds are the first drugs 
given to infected patients. 
Recently, however, traditional chemotherapies are not working due to drug resistance.  
Leishmania donovani isolates have increasingly shown resistance to SAG and as of 2003 it was 
estimated that ten-percent, a rising statistic, of all Leishmania parasites are resistant to this 
treatment (Sundar et al 2000; Abdo et al).  Resistance has skyrocketed in India; rates of 
resistance as high as sixty-percent have been seen in Bihar (Thakur et al 2004).  In fact, 
antimony resistance is so common in India today that patients do not even receive this initial 
treatment line.  
This rapid appearing non-responsiveness to antimonial compounds has pushed for the 
discovery of a second line of treatment, amphotericin B (ampB), an antiprotozoal medication 
available in intravenous, liposomal preparations (Kumar et al 2009).  Considered a drug of last 
resort due to its greater toxicity and potency, ampB can be given to patients at recommended 
dosages no higher than 10 mg/kg over several days (Kafetzisa et al 2005), although there are a 
variety of different treatment regiments.  Its side effects are severe and potentially lethal, 
including high fever, hypertension, anorexia, dyspnea and tachypnea, and nephrotoxicity 
(Lahiado-Laborin et al 2009).  Initial doses should be low and increase every day to prevent a 
serious acute reaction to the compound.  According to a recent study, the effect of ampB 
treatment is due to sterol complexation, both with ergosterol of the Leishmania membrane and 
cholesterol of host macrophages, inhibiting the binding and entry of promastigotes (Paila et al 
2010).  Resistance to ampB has yet to be detected in wild type parasites, however it has emerged 
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in L. donovani clinical isolates in the laboratory (Purkait et al 2012).  The mechanism by which 
these parasites are producing resistant strains so quickly is unclear and could stem from several 
factors. 
There is a third alternate treatment for visceral leishmaniasis approved for use in many 
endemic countries such as Brazil, India, Pakistan, and Afghanistan, called miltefosine.  The 
phospholipid drug acts as an Akt (protein kinase B) inhibitor and was named by a 2005 survey 
the most effective oral treatment for both forms of leishmaniasis (Dorlo et al 2012; Berman).  
“Up to date, more than 2500 patients have been treated with miltefosine in India obtaining cure 
rates over 91% when a dose of 2.5 mg/kg/day during twenty-eight days was prescribed,” (Soto et 
al 2006), but the long-term safety of the drug is still in question; sufficient evidence is lacking in 
terms of its pharmacology and toxicology. 
Due to minimal treatment options, Leishmania research is continually performed, 
especially in regards to genomics and proteomics.  The pathogenicity of Leishmania donovani 
has yet to be attributed to a specific factor.  However, it is known that these parasites secrete a 
lipase (LdLip3) that may contribute to its survival within the human host, development, or 
virulence.  Infectious organisms such as Mycobacterium tuberculosis, Candida albicans, and 
Staphylococcus warneri all produce lipases that aid in their pathogenicity or survival (Cotes et al 
2008; Schaller et al 2005; van Kampen et al 2001), thus we suspect that LdLip3 may mimic 
these lipases in their functions.  It is hypothesized that LdLip3 may disrupt cell signaling, play a 
role in the catabolism of lipids via β-oxidation for nutrients since they are lipid scavengers, or 
directly destroy host tissues.  Shakarian et al (2010) proved that LdLip3 mRNA is constitutively 
expressed by both the promastigote and amastigote.  Lipases are enzymes which hydrolyze, or 
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cleave, the ester bonds in fats releasing glycerol and free fatty acid chains.  Metal ions often are 
cofactors for enzymes like LdLip3, increasing their activity.     
LdLip3 appears to be vitally important, still its particular function has not been found.  
The structure of LdLip3 has also yet to be assembled.  Such information can lend great aid to 
discovering its role in Leishmania’s life cycle.  Over the past several years, we have managed to 
characterize LdLip3 by identifying the protein’s optimal conditions, purifying the enzyme, and 
showing that the addition of metal ions greatly effects enzymatic activity, suggesting possible 
cofactors.  Information about the protein will eventually lead to potential drug targets and better 
methods in diagnosing, treating, and preventing visceral leishmaniasis.   
 
Materials and Methods 
LdLip3 Activity with the Addition of Various Salts 
  
The leishmanial vector pKSNEO is a plasmid, or a circular piece of DNA, which has 
been previously used a multitude of times to express genes associated with different Leishmania 
species (Charest et al 1996; Debrabant et al 2000; Shakarian et al 2010).  In order to study and 
characterize LdLip3 it has to be specifically selected for and isolated.  This is done by first 
genetically modifying pKSNEO to include both the lipase gene (LdLip3) and also a human 
influenza hemagglutinin (HA) tag.  An HA tag codes for a glycoprotein that is generally utilized 
as an epitope tag in expression vectors, as we demonstrate here, facilitating the detection, 
isolation, and purification of recombinant proteins.  Once LdLip3::HA was ligated into pKSNEO 
by Shakarian et al (2010), the plasmid was then transfected into wild type L. donovani 
promastigotes.  The new transfectants were subsequently cultured in chemically defined M199+ 
medium with ten-percent fetal bovine serum and 100 µg/mL of the selective agent G418 
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(Geneticin).  G418 is an antibiotic that blocks polypeptide synthesis in eukaryotic cells (Eustice 
and Wilhelm 1984).  Resistance is conferred by the NEO gene, hence its inclusion within 
pKSNEO.  The cells that took up and contain the plasmid will be resistant to the dissolved G418 
and be able to grow in its presence, while the ones that do not will die.  Growth indicates that 
those cells can overexpress the LdLip3 gene.  Another set of cells were transfected with a non-
chimeric pKSNEO, which acted as a control since these cells would not overexpress LdLip3.  
The cultures were maintained at 26°C in ventilated culture flasks and passaged weekly.   
When the parasitic cultures were mid-log phase (about 4.7x107 cells/mL) the supernatants 
were harvested by centrifugation at 2400×g and 4°C for fifteen minutes.  These samples were 
then used for experimentation.  The supernatant, or the surrounding media, is where the lipase is 
located because its encoding gene contains a signal sequence that directs the protein into the 
cell’s secretory pathway, thus LdLip3 is found outside the cell.   
4-Methylumbelliferone (4-MU) is a florescent molecule which provides an effective and 
accurate method in measuring enzymatic activity in biological assays.  Known concentrations of 
4-MU dissolved in dimethylformamide (DMF) were used to generate a standard curve so as to 
compare the actual samples.  The lipid substrate used was 4-MU palmitate, a sixteen-carbon 
chained fatty acid.  The 4-MU in this molecule replaces the glycerol portion of the fat and when 
cleaved by a lipase, 4-MU fluoresces.  From this, fluorescence is directly proportional to the 
amount of enzymatic activity there is in a sample.  In earlier studies performed by Ganim et al 
(2011), more enzymatic activity was apparent with longer chained substrates, hence the use of 4-
MU palmitate in the detection of lipolytic activity.   
To ensure that LdLip3 is the only esterase acting on 4-MU palmitate, it was necessary to 
purify the original crude supernatant samples, which consist of a mixture of proteins.  Anti-HA 
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protein G affinity matrix columns from Roche were used to purify LdLip3::HA. The HA tag 
initially attached to LdLip3 and ligated into the plasmid is probed for by the antibody in the 
affinity resin which identifies the amino acid sequence YPYDVPDYA (“Anti-HA Affinity 
Matrix from rat IgG1”).  This sequence was recognized in our fusion protein.  The supernatants 
from both sets of transfectants, pKSNEO and pKSNEO::LdLip3::HA, were run on the columns.  
The columns were first equilibrated and then loaded with the 1x supernatants.  The purified 
samples were collected in three separate elution fractions which were later pooled together for 
use in the enzyme activity assays.   
The eluted samples were subjected to a bicinchoninic acid (BCA) assay to determine 
purified protein concentrations.  After incubation for thirty minutes at 37°C, a SPECTRAmax 
M2 spectrophotometer was used to read a clear ninety-six well flat bottom microplate to measure 
the amount of protein (mg) in each sample by comparing the raw data to a standard curve 
constructed by known BSA protein standards.  Visually, the total protein concentration is 
exhibited by a color change from green to purple.  In the BCA assay, the peptide bonds within 
the purified LdLip3 reduce Cu2+ ions to Cu+.  Next, bicinchoninic acid chelates each Cu+ ion, 
forming a purple-colored product that strongly absorbs light at a wavelength of 562 nm 
(Wiechelman et al 1988). 
Enzymatic activity assays were prepared with 89% McIlvaine’s buffer pH 4-8, 5% 
purified sample, 3% 4-MU palmitate, and 3% 1M salt solution.  A sample containing only the 
purified LdLip3, without the addition of any salt, was also loaded on each microplate to establish 
the percent difference in lipase activity when comparing it with the samples with salt.  It has 
been shown that metal ions often act as cofactors for enzymes, increasing their activity (Kumar 
et al 2005).  Here, we test an entire panel of ions, including Zn2+, K+, Na+, Cu2+, Ca2+, Mg2+, 
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Co2+, Fe2+, and Mn2+, to assess their effect on LdLip3.  Analyzing a variety of metal ions will 
yield more information on the enzyme’s preferable conditions.  The Leishmania cell is 
constantly encountering significantly different pHs during its life cycle, therefore a range of pHs 
must be tested to discover LdLip3’s optimal pH where it functions at Vmax.  The unit of Vmax is 
defined as the maximum initial velocity or rate of a catalytic reaction, or in other words, the rate 
at which an enzyme is operating most efficiently.  Sandflies have an acidic thoracic midgut at a 
pH of 6.8, while the human bloodstream is fairly neutral at pH 7.4 (Nestor Añez et al 2003; 
Waugh 22).  The pH in the phagolysosomal system is much lower at 5.7 (Cech and Lehrer 
1984).  Assays were incubated for thirty minutes at one of three biologically relevant 
temperatures.  The temperature within the midgut of the sandfly is around 26°C.  Normal human 
body temperature is 37°C and the feverish human body temperature is 42°C.  Following 
incubations, stop buffers (1M NaOH/1M glycine, and 0.75M NaOH/1M glycine) were added to 
the wells in order to terminate the reactions.  A SPECTRAmax M2 fluorometer read the black 
ninety-six well flat bottom microplates at emission and excitement wavelengths 365 nm and 460 
nm, respectively, to determine the amount of lipase activity (nmol) in each well.  The samples 
were assayed in quadruplicate for reproducibility measurements.  A 4-MU standard curve was 
formed with standards at increasing concentrations from 0.25µM to 500µM and was used to 
deduce the amount of fluorescent product present.  Results from the BCA assay and salted 
activity assays were used to calculate the specific activity (pmol/min/mg) of LdLip3 along with 
the percent difference in net lipase activity. 
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EDTA as a Chelating Agent 
 
 
To ensure the activity changes observed with LdLip3 were in fact due to the addition of 
various metal ions, EDTA, a chelating agent, was added to the samples.  Chelators bind metal 
atoms to ligands within the compound to form a heterocyclic ring containing the metal atom, 
thus the metal ions are unable to interact with the enzyme.  EDTA has previously been used to 
negate the effects of the metal ions in other studies (Park et al 2008).  Activity assays were 
prepared as previously described with the addition of salt and 1M EDTA.  Specific activity was 
again calculated and compared to the activity of purified LdLip3. 
 
Results 
 
A BCA assay was performed before the actual activity assays, but its results were later 
combined with the data collected from said activity assays in order to generate the specific 
activity of both the 1x and purified protein.  Results indicated an average thirty fold increase in 
activity in comparing the purified samples to the 1x supernatants as displayed below (Figure 1).  
This demonstrates that even though there is less protein present in each sample, purified lipase 
produces more activity than unpurified lipase. 
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Figure 1.  Specific Activity of 1x Supernatant in Comparison to Purified LdLip3  
Comparing specific activity of 1x supernatants to the purified LdLip3 at three biologically 
relevant temperatures. Even though there is less protein, purified lipase produces more activity 
than unpurified lipase. There was an approximate thirty fold increase in activity. 
 
 
Results from initial assays without the addition of salt conducted by Ganim et al (2011) 
showed optimal conditions for peak LdLip3 activity with 4-MU palmitate at pH 5.0 after 
incubation at 26°C.  From this information, 4-MU palmitate was verified as a good substrate to 
exploit in the continuation of the project; hence it was utilized in the succeeding salted enzymatic 
activity assays.  Nine different metal ions (Zn2+, K+, Na+, Cu2+, Ca2+, Mg2+, Co2+, Fe2+, and 
Mn2+) were added to the activity assays in the form of salt to determine whether there would be 
any activity change.  Specific activity was calculated and then individually compared to the 
purified LdLip3 activity.  Percent difference of net lipase activity was determined using a basic 
equation [(Pure LdLip3 with Salt – Pure LdLip3 without Salt) x 100].  Depending on the assay 
conditions, ZnSO4, KCl, NaCl, MgCl2, CoCl2, FeSO4, CuSO4, and CaCl2 all had variable effects 
on enzymatic activity whereas MnCl2 consistently showed strong inhibitory effects for all three 
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temperatures at every pH.  Optimal conditions for LdLip3 were established at pH 8, 42°C, with 
the addition of Zn+2, when using 4-MU palmitate as the substrate, indicated by the black arrow 
(Figure 2).  These results are in the process of being validated through the same procedures as 
outlined above.  Thus far, data appears to be over eighty percent reproducible.  A summary graph 
shows the data from every assay performed and further highlights which metal ions activated 
LdLip3 and which inhibited the enzyme (Figure 3).  
 
Figure 2. Percent Difference of LdLip3 Activity with the Addition of Various Metal Ions 
Percent difference in net LdLip3 activity with the addition of various metal ions when compared 
to LdLip3 assays without salts at pH 8. The baseline set at 0 represents 100% of purified LdLip3 
activity. Assays were carried out with final salt concentrations of 1 mM at three different 
temperatures at different pHs.  Peak activity was seen at 42°C with the addition of Zn2+ when 
using 4-MU palmitate as the substrate as indicated by the black arrow. 
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Figure 3.  Summary of Percent Difference in Net LdLip3 Activity with Various Cofactors 
Summary graph detailing the results for every assay performed, displaying peak enzyme activity 
for each pH, with the addition of various salts. Individual points indicate the temperature at 
which the peak activity was observed.  Red specifies an activating effect while blue represents an 
inhibitory effect.  Peak activity was seen at 42°C with the addition of Zn2+ when using 4-MU 
palmitate as the substrate as indicated by the red circle. 
 
 
Peak LdLip3 Activity Within Each pH 
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With the addition of EDTA, initial results from the salted activity assays were reversed.  
The original strong decline in enzymatic activity with the addition of Mn2+ was lessened by 
about eight-percent when EDTA was added to the samples at pH 7.  Although the chelating 
agent did not completely return the specific activity of LdLip3 with added Mn2+ to the same 
value as the purified activity with no additional salts, it did mildly decrease the metal ion’s effect 
on the enzyme by about eight-percent, showing that metal ions are indeed affecting LdLip3 
activity.  Our chelator studies are still in progress, but thus far have been somewhat successful in 
reversing the effects of added metal ions. 
 
Figure 4.  Activity Assays with the Addition of Mn2+ and EDTA at pH 7                        
EDTA appears to lessen the inhibitory effect of the manganese ion on LdLip3 by approximately 
eight-percent.   Assay    was carried    out in   the presence of  a final 1mM EDTA  concentration.     
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Discussion 
 As mentioned earlier, Leishmania donovani is a deadly pathogen which causes a 
dangerous disease that puts at risk over twenty five-percent of the entire world’s population.  
With this being said, it is imperative to be able to treat such a severe illness effectively and 
quickly at an affordable price, seeing that the majority of cases take place in under developed 
nations where medical supplies are limited.  Unfortunately, however, as we’ve seen, current 
treatments are detrimental to the patient, costly, and already are experiencing parasite resistance.  
Hence, a quest to find new drug targets and develop novel medications is imminent.  Since it has 
been previously proven that lipases can sometimes act as virulence factors in other pathogenic 
organisms, we hypothesize that LdLip3 may play a significant role in Leishmania’s life cycle 
either as a virulence factor, a means of nutrient breakdown, or a step in the cell signaling process.  
From this, it is necessary to collect more information on the essential enzyme.  As of today, 
LdLip3’s actual function has yet to be fully determined.  Shakarian et al (2010) speculates that 
the protein’s potential functions include “the acquisition of host resources for energy metabolism 
and as simple building blocks for the synthesis of complex parasite lipids important for 
membrane remodeling and structural purposes.”  Thus, here we further characterize LdLip3 by 
establishing the enzyme’s optimal conditions after purification and identifying possible cofactors 
and in turn possible drug targets. 
 Optimal conditions for LdLip3 were found out by performing many assays of which 
provided a lot of information concerning the enzyme.  From this data it was concluded that 
LdLip3 operates most efficiently under specific environmental conditions, at pH 8, 42°C, with 
the addition of Zn+2, using 4-MU palmitate as the substrate.  These experimental circumstances 
are related to the natural conditions that exist within the bloodstream of a feverish human being 
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with alkalosis, or basic blood.  A study conducted by Verde et al (2011) discovered that in a 
group of fifty-five kala-azar patients 75.5% were described with having chronic mixed alkalosis.  
This corresponds to an individual who has had a parasitic infection for a year or longer and has 
spiked a fever in parallel the waves of parasitemia.  People with visceral leishmaniasis usually 
become sick within months, or sometimes as long as years, of when they were initially bitten by 
an infected sandfly (“Parasites – Leishmaniasis”).   
Given the resemblance of these conditions to the genuine biological conditions in 
Leishmania’s life cycle, there is serious evidence that suggests LdLip3 may in fact be a key 
enzyme in nutrient scavenging and salvaging for energy metabolism, specifically fatty acids.  
These fatty acids will be used for the parasite’s growth, attesting that LdLip3 should be targeted 
in drug development.  Enzyme inhibition would be an ideal solution in deactivating LdLip3.  The 
fact that Mn2+ consistently decreased LdLip3 activity offers another direction that drug 
engineering could take.  Instead of blocking the enzyme’s active site with an antagonist similar 
in structure to a fat through competitive inhibition, an allosteric inhibitor could be used to 
deactivate the enzyme.  According to a recent study, LdLip3 inhibitors are in the process of 
being investigated.  The molecule 3,4-dichloro-N-(3-nitrophenyl)benzenesulfonamide might be a 
non-covalent inhibitor based on the Structure Based Drug Design approach using the NCI 
diversity set and ZINC database (Parameswaran et al 2011). 
 Upon protein purification with Anti-HA affinity columns we were able to isolate the 
chimeric protein LdLip3::HA.  Purified specific enzymatic activity increased thirtyfold over the 
unpurified 1x supernatant sample.  This large increase in activity shows that we isolated a 
functional protein that retained enzymatic activity after being genetically modified and 
overexpressed.  Furthermore, we proved that metal ions do have an influence on enzymatic 
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activity, under certain conditions, severely affecting the enzyme’s Vmax.  The addition of Zn2+ 
increased LdLip3 activity by approximately twenty one-percent, demonstrating that it might be 
an important cofactor.   
This research has yielded large amounts of information on the secretory enzyme LdLip3 
and although we have yet to give the protein a definite function in Leishmania donovani’s life 
cycle, we do know that it is produced in great amounts, thus it must serve a critical purpose.  We 
have accomplished many goals in investigating LdLip3, being successful in several biological 
techniques and learning the important of persistence.  In the future, now that we know the 
optimal conditions for LdLip3, inhibitor studies with organophosphates that have been show to 
inhibit lipases (Quistad et al 2006; Quistad, Liang et al 2006) can be conducted using said 
conditions.  The larger objective for this project was to characterize the activity of LdLip3 and 
contribute to the mission in developing new drugs in treating or preventing visceral 
leishmaniasis.  We have triumphed in achieving this long-term goal and hopefully future 
information will arise concerning the enzyme’s function in the deadly human pathogen 
Leishmania donovani.  
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